NVAX

Novavax, Inc. (NVAX) Q1 2026 Filing Summary

Business Context and Reporting Period

This summary covers the Unaudited Consolidated Financial Statements for Novavax, Inc. for the quarterly period ended March 31, 2026. Novavax is a biotechnology company focused on vaccine development, utilizing its proprietary Matrix-M™ adjuvant and protein-based nanoparticle technology. The company's strategy relies on commercializing its COVID-19 vaccine (Nuvaxovid™) through partnerships, primarily with Sanofi, and licensing its adjuvant technology to other pharmaceutical companies.

Key Financial Metrics

Note: Q1 2025 results were significantly impacted by one-time revenue from the termination of Advance Purchase Agreements (APAs) with Canada and New Zealand.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by $527.1 million (79%) compared to Q1 2025. This was driven by a $579.5 million drop in Product Sales, primarily due to the cessation of direct Nuvaxovid sales following the commercial transition to Sanofi and the absence of the one-time $575.7 million Canada APA termination revenue recognized in Q1 2025.
• Licensing Growth: Licensing, royalties, and other revenue increased by $52.3 million to $97.3 million. This increase was largely due to the recognition of a $30 million upfront payment from a new license agreement with Pfizer.
• Profitability Shift: The company reported a net loss of $9.5 million in Q1 2026, a stark contrast to the $518.6 million net income in Q1 2025. The prior year's income was non-recurring, driven by the APA termination settlements.
• Debt Expansion: Long-term debt increased by $46.8 million to $291.0 million, reflecting the funding of $50.0 million under a new Credit Agreement with MidCap Financial Trust in February 2026.

Guidance, Outlook, and Risks

• Strategic Partnerships:
  • Pfizer: Entered a license agreement in January 2026 for the Matrix-M adjuvant in two infectious disease areas, receiving a $30 million upfront payment with up to $500 million in potential milestones.
  • Sanofi: Continued revenue recognition from transition services and technology transfer. Sanofi now leads commercialization of Nuvaxovid globally.
• Liquidity and Going Concern: Management concluded that current cash, cash equivalents, and marketable securities ($794.9 million total) are sufficient to fund operations for at least the next 12 months. The company maintains a financial covenant requiring unrestricted cash of at least $100 million.
• Restructuring: The company continues its global restructuring plan, including the sale of its Gaithersburg, Maryland facility (700 Quince Orchard) to AstraZeneca, receiving $39.8 million in proceeds during the quarter.
• Risks and Contingencies:
  • Australia APA: Australia cancelled certain dose deliveries. Up to $92.5 million of deferred revenue may become refundable if regulatory approval for the updated vaccine is not obtained or doses are not delivered per the amended schedule.
  • UK Settlement: The company is repaying $123.8 million to the UK government in quarterly installments through June 2027 following a settlement of a dispute over upfront payments.
  • Regulatory Dependence: Future revenue is heavily dependent on regulatory approvals for updated COVID-19 vaccines and the success of partner-led commercialization.

Investor Verification Checklist

• Revenue Sustainability: Verify the trajectory of revenue post-transition to Sanofi, specifically the mix of supply sales versus licensing/royalty income.
• Australia APA Status: Monitor the regulatory status of the JN.1 variant vaccine in Australia to assess the risk of the $92.5 million potential refund.
• Cash Burn Rate: Track operating cash flow usage against the $794.9 million liquidity buffer to confirm the 12-month runway.
• Debt Covenants: Confirm continued compliance with the $100 million unrestricted cash covenant under the new Credit Agreement.
• Pfizer Milestone Potential: Assess the likelihood of achieving the $500 million in potential milestones under the new Pfizer adjuvant license.